Innoviva Competitors

Innoviva (NASDAQ:INVA) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

Innoviva has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Innoviva and Amgen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

71.5% of Innoviva shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Innoviva and Amgen's top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Innoviva and Amgen, as provided by MarketBeat.

Innoviva presently has a consensus target price of $10.00, indicating a potential downside of 12.51%. Amgen has a consensus target price of $256.0909, indicating a potential upside of 13.86%. Given Amgen's stronger consensus rating and higher possible upside, analysts plainly believe Amgen is more favorable than Innoviva.

Summary

Amgen beats Innoviva on 12 of the 14 factors compared between the two stocks.

Innoviva (NASDAQ:INVA) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

Innoviva has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares Innoviva and Gilead Sciences' net margins, return on equity and return on assets.

Institutional and Insider Ownership

71.5% of Innoviva shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Innoviva and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Innoviva and Gilead Sciences, as provided by MarketBeat.

Innoviva presently has a consensus target price of $10.00, indicating a potential downside of 12.51%. Gilead Sciences has a consensus target price of $96.0370, indicating a potential upside of 56.41%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Innoviva.

Summary

Gilead Sciences beats Innoviva on 8 of the 14 factors compared between the two stocks.

Innoviva (NASDAQ:INVA) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

Innoviva has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Innoviva and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

71.5% of Innoviva shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Innoviva and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Innoviva and Vertex Pharmaceuticals, as provided by MarketBeat.

Innoviva presently has a consensus target price of $10.00, indicating a potential downside of 12.51%. Vertex Pharmaceuticals has a consensus target price of $291.8462, indicating a potential upside of 37.31%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Innoviva.

Summary

Vertex Pharmaceuticals beats Innoviva on 12 of the 15 factors compared between the two stocks.

Innoviva (NASDAQ:INVA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

Innoviva has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Earnings and Valuation

This table compares Innoviva and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

71.5% of Innoviva shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Innoviva and Regeneron Pharmaceuticals, as provided by MarketBeat.

Innoviva presently has a consensus target price of $10.00, indicating a potential downside of 12.51%. Regeneron Pharmaceuticals has a consensus target price of $625.8077, indicating a potential upside of 38.89%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Innoviva.

Profitability

This table compares Innoviva and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats Innoviva on 11 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Valuation & Earnings

This table compares Biogen and Innoviva's top-line revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 71.5% of Innoviva shares are owned by institutional investors. 0.5% of Biogen shares are owned by company insiders. Comparatively, 0.3% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Biogen and Innoviva, as reported by MarketBeat.com.

Biogen currently has a consensus price target of $304.4667, indicating a potential upside of 11.58%. Innoviva has a consensus price target of $10.00, indicating a potential downside of 12.51%. Given Biogen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biogen is more favorable than Innoviva.

Profitability

This table compares Biogen and Innoviva's net margins, return on equity and return on assets.

Summary

Biogen beats Innoviva on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Innoviva's top-line revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.5% of Innoviva shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Alexion Pharmaceuticals and Innoviva, as reported by MarketBeat.com.

Alexion Pharmaceuticals currently has a consensus price target of $153.1250, indicating a potential upside of 0.25%. Innoviva has a consensus price target of $10.00, indicating a potential downside of 12.51%. Given Alexion Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alexion Pharmaceuticals is more favorable than Innoviva.

Profitability

This table compares Alexion Pharmaceuticals and Innoviva's net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats Innoviva on 12 of the 15 factors compared between the two stocks.